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In immature rodent brain, unilateral intrastriatal in- 
jections of selected excitatory amino acid (EAA) recep- 
tor agonists, such as N-methyl-D-aspartate (NMDA), 
produce prominent ipsilateral forebrain lesions. In 
Postnatal Day (PND) 7 rats that receive a right intra- 
striatal injection of NMDA (25 nmol) and are sacrificed 
5 days later, there is a considerable and consistent re- 
duction in the weight of the injected cerebral hemi- 
sphere relative to that of the contralateral side (-28.5 
f 1.9%, n = 6). In animals treated with specific NMDA 
receptor antagonists, the severity of NMDA-induced 
damage is markedly reduced. We have previously re- 
ported that the efficacy of potential neuroprotective 
drugs in limiting NMDA-induced lesions can be as- 
sessed quantitatively by comparison of hemisphere 
weights after a unilateral NMDA injection. In this 
study, we compared three quantitative methods to eval- 
uate the severity of NMDA-induced brain injury and 
the degree of neuroprotection provided by NMDA re- 
ceptor antagonists. We characterized the severity of 
brain injury resulting from intrastriatal injections of 
l-50 nmol NMDA in PND 7 rats sacrificed on PND 12 
by (i) comparison of cerebral hemisphere weights; (ii) 
assay of the activity of the cholinergic neuronal 
marker, choline acetyltransferase (ChAT) activity; and 
(iii) measurement of regional brain cross-sectional ar- 
eas. The severity of the resulting brain injury as as- 
sessed by comparison of hemisphere weights increased 
linearly with the amount of NMDA injected into the 
striatum up to 25 nmol NMDA. The magnitude of injury 
was highly correlated with the degree of reduction in 
ChAT activity (4 = 0.97). Quantification of neuropro- 
tection against NMDA toxicity by measurement of ce- 
rebral hemisphere weight disparities was highly corre- 
lated with comparisons of hemisphere and striatal 
cross-sectional areas (3 = 0.98). The potency and 
efficacy of the dissociative anesthetic ketamine was eas- 
ily distinguished from those of two other NMDA recep- 
1 To whom correspondence should be addressed at Kennedy Insti- 
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tor antagonists (MK-801, (+)-5-methyl-lO,ll-dihy- 
dro-5H-dibenzo[a,d]cyclohepten-S,lO-immine maleate 
and CPP, 3-((+)-2-carboxypiperazine-4-yl)-propyl-l- 
phosphonic acid) using this model. These data demon- 
strate that this model can be used to accurately quanti- 
tate NMDA-induced brain injury and evaluate neuro- 
protective properties of glutamate antagonists in 
vivo. 0 1999 Academic Press, Inc. 
INTRODUCTION 
Selected EAA receptor agonists are neurotoxic in both 
the developing (5,19,28,31) and the mature (6,10,32) 
rat brain. The neurotoxicity of NMDA is markedly en- 
hanced in developing rat brain (15,19). Studies carried 
out both in uiuo and in vitro demonstrate that competi- 
tive and noncompetitive antagonists of NMDA recep- 
tors protect against neuronal injury produced by NMDA 
(4, 11, 12, 20, 22, 23). Antagonism of NMDA receptors 
similarily limits neuronal injury resulting from hypoxia- 
ischemia (3,8,12, l&29,33). 
These observations have raised considerable interest 
in the potential therapeutic applications of NMDA an- 
tagonists. Rapid and sensitive methods to quantitate the 
in uiuo neuroprotective effects of such compounds are 
needed. Most in uiuo models of brain injury have relied 
on anatomical or biochemical approaches to quantitate 
the severity of injury and efficacy of neuroprotective 
agents. Cell counts, histopathologic cross-sectional area 
measurements, and activity of specific neuronal markers 
such as ChAT activity and neuron-specific immunoreac- 
tivity are commonly used as indices of neuronal injury 
(2,6, 7,8, 18, 23). Recent in vitro assays of injury using 
neuronal cell cultures have been refined to provide useful 
quantitative neuroprotection data (4, 9, 16). However, 
results from in vitro studies may not accurately reflect 
in uiuo effects. 
We have recently developed an in uiuo method for 
quantification of neuroprotection against NMDA-medi- 
ated brain injury in perinatal rats (20, 22). This model 
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takes advantage of the enhanced toxicity of NMDA in 
PND 7 rats (19). During this phase of rapid develop- 
ment, focal brain damage results in reduced growth of 
the injured cerebral hemisphere over a several day sur- 
vival period. In animals sacrificed 5 days after a unilat- 
eral NMDA injection, measurement of disparities be- 
tween NMDA injected and contralateral cerebral hemi- 
sphere weights appears to be a good indicator of brain 
injury (22). 
To determine the validity of hemisphere weight mea- 
surements as an index of neuronal injury, we compared 
measurements of hemisphere weights to two more fre- 
quently used methods; measurements of (i) tissue ChAT 
activity and (ii) regional cross-sectional areas in histo- 
pathologic sections. The sensitivity of this model was as- 
sessed by comparing the neuroprotective effects of one 
competitive (CPP) and two noncompetitive (MK-801 
ketamine) NMDA receptor antagonists against NMDA- 
mediated brain injury. The results demonstrate that 
comparison of cerebral hemisphere weights can be used 
as an accurate method for quantifying the effects of po- 
tential neuroprotective compounds. 
METHODS 
Experimental Protocols 
PND 7 male and female Sprague-Dawley albino rats, 
weighing between 12 and 18 g, were used for all experi- 
ments. Rats were anesthetized with diethyl ether for 3 
min. Intrastriatal injections of NMDA were performed 
as described below. All animals were sacrificed on PND 
12,5 days after intrastriatal NMDA injection- 
To determine the relationship between the amount of 
NMDA injected into the striatum and the degree of re- 
sulting brain injury six doses of NMDA were used: 1 
nmol, n = 5; 5 nmol, n = 5; 10 nmol, n = 5; 17 nmol, n 
= 5; 25 nmol, n = 6; and 50 nmol, n = 2. Brain injury was 
assessed first by comparison of injected and contralat- 
era1 hemisphere weights as described below and then by 
assay of ChAT activity in the corpus striatum and dorsal 
hippocampus bilaterally in the same brains. 
To further evaluate the reliability of measurements of 
hemisphere weights as an index of neuronal injury, 
hemisphere weight measurements were compared to 
measurements of regional cross-sectional areas in ani- 
mals that received NMDA (25 nmol) and one of four 
doses of MK-801. A single dose of MK-801 (ip injection 
in 0.05 ml PBS) was administered 30 min prior to intra- 
striatal injection of NMDA (25 nmol/0.5 ~1). Four doses 
of MK-801 were used: 0.1, 0.25, 0.5, and 1.0 mg/kg (n 
= 9,7,13, and 8, respectively); NMDA-injected controls 
received ip injections of an equivalent volume of PBS 
instead of MK-801 (n = 28). Animals were sacrificed 5 
days later. Quantitation of neuroprotection by area mea- 
surements was compared with quantitation using dis- 
parities between cerebral hemisphere weights in an addi- 
tional group of animals (doses of MK-801 tested: 0.1, 
0.25,0.5, and 1.0 mg/kg; n = 8,9,6, and 8, respectively; 
controls received intrastriatal NMDA injection and 
PBS ip, n = 20). 
The sensitivity of this model was tested by assessing 
the neuroprotective effects of ketamine, a noncompeti- 
tive NMDA antagonist, against NMDA-mediated brain 
injury in doses ranging from 12 to 183 pmol/kg. Six to 
ten rats were tested at each of six doses. Also, four to six 
NMDA-injected, PBS-treated controls were included at 
each dose tested. Results were compared with previously 
reported dose-response relationships of neuroprotec- 
tion against NMDA toxicity for one competitive (CPP) 
and one noncompetitive (MK-801) NMDA receptor an- 
tagonist (22). Neuroprotection was assessed by measure- 
ment of cerebral hemisphere weight disparities. 
Intracerebral Injections 
Injections were performed as previously described (20, 
22). Briefly, PND 7 rats were anesthetized with ether 
and a midline scalp incision was made to expose the cal- 
varium. Pups were positioned in a plaster of paris mold 
of the head and body. Intracerebral stereotaxic injec- 
tions were performed with a 26-gauge, beveled tip, Ham- 
ilton syringe using a Kopf small animal apparatus. Injec- 
tions were made through a hole pierced in the skull using 
a 25-gauge needle (the skull is very pliable at this devel- 
opmental age). The site of injection was determined in 
preliminary experiments and was chosen to simulate the 
lesion produced in an established perinatal model of fo- 
cal hypoxic-ischemic brain injury by unilateral carotid 
ligation and timed exposure to moderate hypoxia (14, 
18). All intracerebral injections were made in the poste- 
rior striatum. Using bregma as a landmark, injection site 
coordinates were AP 2.0 mm and L 2.5 mm, at a depth 
of 4 mm from the dura. The needle was left in place for 
2 min following injection to limit leakage. 
NMDA was dissolved in 0.01 M Tris-buffer, pH 7.4. 
Pups received varying amounts of NMDA intrastriatally 
in a volume of 0.5 ~1. Preliminary experiments indicated 
that 0.5 ~1 is the largest volume that can be accurately 
and reliably administered intracerebrally in perinatal 
rats. 
The scalp was sutured with 6-O nylon suture. Rats 
were subsequently placed under a warming lamp set to 
maintain a 37°C body temperature for 2 h, maintenance 
of correct body temperature is critical in this model 
(data not shown). This period ensured adequate recov- 
ery from anesthesia and allowed behavioral observa- 
tions. Pups were then returned to their mother. Five 
days later, on PND 12, animals were sacrificed by decap- 
itation. 
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Quantification of Brain Injury by Comparison of 
Cerebral Hemisphere Weights 
The forebrain was separated from the cerebellum and 
brain stem using a razor blade. The two cerebral hemi- 
spheres were separated, weighed, and then either frozen 
for subsequent biochemical assays or placed in 10% pho- 
sphate-buffered formalin solution for histology. 
Hemisphere weight disparities were compared for 
each animal using the formula 100 * (C-1)/C = % dam- 
age, a value that reflects the severity of damage of the 
injected (I) cerebral hemisphere relative to that of the 
contralateral (C) hemisphere. Values presented are 
means + SEM. 
Choline Acetyltransferase Assay 
Striatal and hippocampal tissues from the same ani- 
mals used to develop the dose-response relationship for 
NMDA-mediated brain injury were dissected out on ice 
and then homogenized 1:20 in 50 mM Tris (pH 7.4) plus 
0.02% Triton X-100. Brain tissue was assayed for ChAT 
activity by a modification of a previously described 
method (27). ChAT activity (nmol/min/mg protein) was 
expressed as percentage decrease in the injected hemi- 
sphere relative to that of the contralateral hemisphere, 
% decrease = 100 * (C-I)/! = % damage. 
Cross-sectional Area Measurements 
Whole brains were placed sequentially into 10% phos- 
phate-buffered formalin (PBF) followed by a 30% su- 
crose/PBF solution. Fifty-micrometer frozen coronal 
brain sections were stained for Nissl substance with cre- 
syl violet. Tissue damage was quantitated by measure- 
ment of cross-sectional areas of the corpus striatum and 
the entire cerebral hemisphere using a video-based com- 
puterized image analyzer (Imaging Research, St. Cath- 
erines, Ontario). For each animal, measurements were 
made bilaterally in four coronal sections at the level of 
the striatum. The four measures for each structure were 
summed within animals by hemisphere; NMDA injected 
and contralateral hemisphere values were compared as 
described above for hemisphere weights. Data were 
expressed as percentage protection, mean + SEM (see 
below). 
Neuroprotection Studies 
NMDA antagonists were administered ip in 0.05 ml 
phosphate-buffered saline (PBS),pH 7.4. In preliminary 
experiments, this injection volume was determined to 
maximize consistency of drug delivery. Pups were 
treated with neuroprotective compounds 15 min after in- 
trastriatal injection of 25 nmol NMDA (20,22). This de- 
lay was chosen to allow partial recovery from anesthesia 
and to limit interactions between the ether anesthesia 
and NMDA antagonists. Animals were sacrificed 5 days 
later. 
Data are expressed as percent protection against 
NMDA toxicity using the formula: 
% Protection = lOO* (1 - [% damage drug treated/ 
% damage PBS treated]). 
Percent damage values for experimental groups that re- 
ceived NMDA plus a NMDA receptor antagonist were 
compared with those of controls that received NMDA 
and PBS. Percentage protection values were expressed 
as mean f SEM. The SEM was calculated: 
SEM (% protection) = 100 * (SEM, drug treated/ 
% damage PBS treated). 
The doses that produced 50% protection were deter- 
mined by probit analysis according to the method of 
Litchfield and Wilcoxon ( 17). 
RESULTS 
Unilateral intracerebral administration of nanomolar 
quantities of NMDA in PND 7 rats typically produced 
tonic and tonic-clonic seizure-like activity, and in ani- 
mals sacrificed 5 days later, there was unilateral gross 
hemisphere deformity and confluent brain necrosis in 
striatum which extended into adjacent areas: neocortex, 
dorsal hippocampus, and thalamus (Figs. 1A and 1B). 
Damage in regions adjacent to the striatum probably re- 
flects diffusion of NMDA from the injection site. Tissue 
damage was usually confined to the injected hemisphere; 
histologic examination occasionally revealed micro- 
scopic injury in the opposite cerebral hemisphere. In ani- 
mals injected with 25 nmol NMDA, the weight of the 
injected hemisphere relative to the contralateral hemi- 
sphere (percent damage) was reduced by an average of 
28.5 + 1.9%, n = 6 (Fig. 2). Among the animals used in 
the NMDA dose-response experiments, the mortality 
rate was equivalent in groups that received 25 nmol 
NMDA or less (13% mortality, n = G/group). Treatment 
with NMDA receptor antagonists substantially reduced 
the mortality rate (<2% at intermediate doses/drug). In- 
jection of vehicle produced few signs of brain injury (% 
damage = -0.6 rfr 0.7%, n = 5). 
The severity of brain injury produced by intrastriatal 
injection of NMDA, percent damage, increased lin- 
early with the amount of NMDA injected up to at least 
25 nmol NMDA (Fig. 2). Linear regression analysis indi- 
cated an associated correlation coefficient of 0.99. Doses 
of NMDA greater than 25 nmol NMDA deviated from 
this linear relationship. Injection of 50 nmol NMDA oc- 
casionally resulted in obvious contralateral hemisphere 
292 MCDONALD ET AL. 
SALINE MK-80 1 
FIG. 1. NMDA-induced brain injury in brains of 12-day-old rats 
that received a unilateral intrastriatal injection of 25 nmol NMDA on 
PND 7. NMDA was stereotaxically injected into the posterior stria- 
turn in a volume of 0.5 ~1. Animals were administered a single dose of 
either saline or 1 mg/kg MK-801 intraperitoneally 15 min after intra- 
striatal NMDA injection. (A) Representative brains of perinatal rats 
that received a right intrastriatal injection of NMDA and were treated 
with either “saline” or “MK-801.” Intrastriatal injection of NMDA 
produced extensive damage in the injected hemisphere (A, saline). 
There were no obvious signs of injury in the contralateral hemisphere 
(A, MK-801). (B) Representative Nissl-stained coronal brain sections 
from the same brains presented in A. The NMDA-induced lesion is 
characterized by confluent necrosis in the corpus striatum, extending 
into the neocortex (B, saline). Damage extends caudally into the dor- 
sal hippocampus and thalamus. In contrast, treatment with 1 mg/kg 
MK-801 eliminated obvious signs of neuronal injury (B, MK-801). 
injury in addition to the typical ipsilateral damage. With 
the exception of 50 nmol NMDA, doses of 25 nmol or less 
did not affect the weight of the noninjected hemisphere 
relative to that of noninjected controls (p = ns, ANOVA, 
weights of uninjected hemisphere, control, 415 + 15 g vs 
NMDA 1 nmol, 419 f 11; 5 nmol, 419 f 9; 10 nmol, 413 
f 16; 17 nmol, 384 + 19; 25 nmol, 403 + 11, n = 5-6/ 
group; 50 nmol, 326 f 27, n = 2). In contrast to the con- 
fluent necrosis produced by 25 nmol NMDA (see Fig. 1) , 
injection of 5 or 10 nmol NMDA typically resulted in 
more selective neuronal necrosis with relative sparing of 
some neurons. 
ChAT activity in the striatum of the same rats used in 
the NMDA dose-response experiments was reduced by 
intrastriatal injection of NMDA in a dose-dependent 
manner (Fig. 3). Similarly, reduction of hippocampal 
ChAT activity was highly correlated with the amount of 
NMDA injected (? = 0.88). However, since the NMDA 
injection was not delivered directly into the hippocam- 
pus, the lowest doses of NMDA did not alter hippocam- 
pal ChAT activity. With the exception of 50 nmol 
NMDA, injection of l-25 nmol NMDA did not alter 
ChAT activity in the hemisphere contralateral to the in- 
jected hemisphere when compared to that of noninjected 
controls. The degree of brain injury (expressed as per- 
cent damage) resulting from intrastriatal injection of in- 
creasing amounts of NMDA was linearly related to the 
percentage decrease in ChAT activity in both striatum 
and hippocampus (Figs. 4A and 4B). Linear regression 
analysis indicated associated correlation coefficients of 
0.97 and 0.90 in striatum and hippocampus, respectively. 
Intrastriatal injection of 25 nmol NMDA produced a 
consistent reduction in the cross-sectional areas of the 
injected striatum and cerebral hemisphere relative to 
that of the contralateral side. NMDA injected striatal 
cross-sectional areas were reduced by 59.6 f 3.1% rela- 
tive to the contralateral striatum, and the cross-sec- 
tional areas of the entire cerebral hemisphere at the level 
of the striatum were reduced by 36.9 + 3.2% (n = 28). 
We had previously found that the noncompetitive 
NMDA antagonist MK-801 produced dose-dependent 
neuroprotection against NMDA-mediated brain injury 
assessed by comparison of hemisphere weights (20,22). 
The level of neuroprotection achieved by four doses of 
MK-801 (0.1, 0.25, 0.5, 1.0 mg/kg) was similar when 
quantified by either compariscn of cerebral hemisphere 
cross-sectional areas or comparison of cerebral hemi- 
sphere weights (Fig. 5). Regression analysis indicated a 
linear relationship between these two methods of quan- 
tifying neuroprotection against NMDA toxicity (? 
= 0.98). A similar relationship was obtained when cross- 
sectional area values of the striatum were used (? 
= 0.97). 
The dissociative anesthetic ketamine produced dose- 
dependent neuroprotection when increasing dosages 
were administered ip 15 min after unilateral intracere- 
bra1 injection of 25 nmol NMDA (Fig. 6). However, com- 
parison with data reported previously describing the 
neuroprotective properties of MK-801 and the competi- 
tive NMDA antagonist, CPP, indicates that ketamine is 
a relatively poor neuroprotective agent in this model 
(22) (Fig. 6). MK-801 was the most potent neuroprotec- 
tant with a 50% protective dose of 0.63 pmol/kg (95% 
confidence limits = 0.22, 1.81). Similar values for keta- 
mine and CPP were 113.68 (36.30, 356.02) and 8.84 
(3.93,19.88), respectively. The maximal levels of neuro- 
protection against NMDA toxicity were MK-801,94.89 
+ 3.95%, 4.17 pmol/kg; ketamine, 68.21 f 3.4%, 182.66 
pmol/kg; and CPP, 84.42 f 3.03%, 51.38 pmol/kg). 
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FIG. 2. Relationship between the amount of NMDA injected into the striatum and the degree of resulting brain injury quantitated by 
measurement of cerebral hemisphere weight disparities. PND 7 rats received unilateral intrastriatal injections of NMDA in amounts increasing 
from 1 to 50 nmol. Five days later the animals were sacrificed. Brain damage was quantitated by comparison of the weights of the injected (I) 
and contralateral (C) cerebral hemispheres using the equation indicated on the vertical axis. Brain injury (%damage) increased linearly with 
the amount of NMDA injected into the striatum up to at least 25 nmol NMDA. Values represent the means + SEM: 1 nmol, n = 5; 5 nmol, n 
= 5; 10 nmol, n = 5; 17 nmol, n = 5; 25 nmol, n = 6; and 50 nmol, n = 2. The inset illustrates the linear relationship between amount of NMDA 
injected (l-25 nmol) and %damage (correlation coefficient = 0.99). 
Treatment with these neuroprotective compounds re- 
duced the mortality rate to close to zero depending on 
the dosages used. However, high doses of all these com- 
pounds increased mortality above the level of NMDA in- 
jected controls. Ketamine dosages greater than 33 pmol/ 
kg resulted in marked mortality rates; 75% mortality 
was observed at the maximally protective dose of 183 
pmol/kg and 37.5% at 120 pmol/kg. 
DISCUSSION 
Recent studies implicating over activation of EAA re- 
ceptors in the pathogenesis of neurologic disorders have 
stimulated the development of drugs designed to limit 
neuronal injury by blocking activation of these receptors 
(13, 18, 25, 26, 29). Effective and efficient methods to 
study the neuroprotective properties of these com- 
pounds against brain injury in uiuo are needed. Quanti- 
tation of brain injury is difficult. Established methods 
used to assess neuronal injury and neuroprotection in 
viuo have relied on biochemical and anatomical mea- 
sures of tissue integrity, e.g., measurement of activity of 
neuronal-specific enzymes, neuronal-specific immuno- 
reactivity, cross-sectional area measurements, and cell 
counts in lesioned tissue (2,6-8,19,23). We have char- 
acterized a perinatal rat model of NMDA-induced brain 
injury as a method for quantifying the effectiveness of 
potential neuroprotective compounds by simply com- 
paring the weights of the injected and contralateral cere- 
bral hemisphere weights (22). This study demonstrates 
that quantitation of brain injury by this method is as 
sensitive and accurate as two of the more traditional bio- 
chemical and anatomical methods cited above. The data 
presented here indicate that in this model changes in ce- 
rebral hemisphere weight closely reflect the extent of 
neuronal damage. 
The severity of brain injury resulting from intrastria- 
tal injection of NMDA, as assessed by hemisphere 
weight disparities, is linearly related to the amount of 
NMDA injected into the striatum. In PND 7 rats, injec- 
tion of 25 nmol NMDA reliably produces about a 30% 
decrease in the weight of the injected hemisphere rela- 
tive to that of the contralateral hemisphere (22). This 
dose of NMDA maximizes the severity of brain injury 
while maintaining a low level of mortality (13% mortal- 
ity rate). The developing brain is more susceptible to 
NMDA-mediated brain injury than the adult brain (15, 
19). NMDA appears to produce about 60 times as much 
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FIG. 3. Relationship between reductions in striatal ChAT activ- 
ity and amount of NMDA injected intrastriatally in PND 7 rats. 
Amounts of NMDA from 1 to 50 nmol were injected intrastriatally as 
described in Fig. 2 and animals were sacrificed 5 days later. ChAT 
activity was measured bilaterally in the striatum of the same animals 
included in Fig. 2 (see Materials and Methods). Reductions in ChAT 
activity in the injected striatum were expressed relative to those in 
the contralateral striatum using the equation indicated on the vertical 
axis. Error bars represent the SEM for the number of animals indi- 
cated in Fig. 2. 
brain damage in 7-day-old rats as compared to adults 
(19). This enhanced responsiveness to NMDA neuro- 
toxicity facilitates quantification of injury by compari- 
son of hemisphere weights. 
The severity of NMDA-mediated brain injury is lin- 
early related to reductions in ChAT activity. Since 
ChAT activity is a specific marker of cholinergic neu- 
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rons, this observation supports the validity of compari- 
son of hemisphere weights of NMDA-injected animals 
as a quantitative measure of neuronal injury. As well, 
quantitation of neuroprotection, produced by different 
doses of MK-801, by comparison of hemisphere weights 
corresponds closely to similar comparisons of cerebral 
hemisphere and striatal cross-sectional areas. 
This model is a rapid and sensitive method for evalu- 
ating the effectiveness of EAA receptor antagonist as 
well as neuroprotective effects of ions and non-NMDA 
receptor ligands against NMDA-mediated brain injury 
(20-22). Potencies and maximal effectiveness of neuro- 
protective compounds can readily be distinguished. The 
potencies of NMDA receptor antagonists in this model 
correspond roughly with their receptor affinities in bind- 
ing studies as well as with their potencies as anticonvul- 
sants (20-22). However, the potency of ketamine rela- 
tive to MK-801 is much lower than expected on the basis 
of binding affinities. This disparity probably reflects 
effects not present in uitro. Furthermore, it is apparent 
that the degree of neuroprotection produced by a partic- 
ular compound is not always related to its anticonvul- 
sant properties (20-22). For instance, MK-801 produces 
significant levels of neuroprotection at doses that do not 
block behavioral signs of seizures (22). Also, anticonvul- 
sants such as phenytoin, diazepam, and the calcium an- 
tagonist flunarizine do not block NMDA-induced injury 
in this model even though they prevent seizure activ- 
ity (20). 
Finally, the present model of NMDA-induced brain 
injury and perinatal rat models of hypoxic-ischemic 
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FIG. 4. Comparison of two methods of quantifying NMDA-mediated brain injury in perinatal rats: measurement of hemisphere weight 
disparities and ChAT activity. Intrastriatal injections of NMDA (l-50 nmol) were performed as described in Fig. 2. Brain injury was assessed 
by measurement of cerebral hemisphere weights and by measurement of ChAT activity in the same brains. Data are expressed as percent 
decrease in the weight or in ChAT activity of the injected hemisphere relative to that of the contralateral hemisphere. Striatal (A) and hippocam- 
pal (B) tissue were used to assay ChAT activity (see Materials and Methods for assay methods). There is a positive linear correlation between 
percent decrease in cerebral hemisphere weight and percent decrease in ChAT activity. The lines shown were fit by linear regression. 
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FIG. 5. Comparison of two methods for quantification of neuroprotection against NMDA-mediated brain injury. Four doses (0.1,0.25,0.5, 
and 1.0 mg/kg) of the noncompetitive NMDA antagonist MK-801 were administered (ip, in 0.05 ml PBS) 30 min prior to unilateral intrastriatal 
injection of NMDA (25 nmol/0.5 ~1) in PND 7 rats. Five days later animals were sacrificed. The degree of neuroprotection was quantified in 
independent groups of animals either by comparison of NMDA-injected and contralateral whole hemisphere (A) and striatal (B) cross-sectional 
areas measured with a video-based image analysis system or by comparison of cerebral hemisphere weights. Linear regression analysis indicated 
a high degree of concordance between these two methods for quantification of neuroprotection (3 = 0.98, cerebral hemisphere; ? = 0.97, 
striatum). Error bars represent SEM. Six to 13 animals per dose were used for each method. 
NMDA-mediated brain damage is very similar to that 
produced by hypoxia-ischemia (14, 18, 23) and hypo- 
baric-ischemia (15) at this developmental stage. Suscep- 
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FIG. 6. The quantitative neuroprotective characteristics of keta- 
mine against NMDA-induced brain injury are compared with the 
effects of noncompetitive (MK-801) and competitive (CPP) NMDA 
receptor antagonists (22). Brain injury was assessed by comparison of 
hemisphere weight disparities in the brains of PND 12 rats. Neuropro- 
tective drugs were administered (ip, 0.05 ml PBS) 15 min after intra- 
striatal injection of NMDA (25 nmol, 0.5 ~1) in PND 7 rats (n = 6-10 
per dose). Saline-treated, NMDA-injected littermate controls (n = 4- 
6) were included at each dose. Animals were sacrificed 5 days later. 
Percent protection values were derived by comparison of hemisphere 
weight disparities of drug-treated and saline-treated groups (see Mate- 
rials and Methods for details). Values are expressed as means + SEM. 
siently peaks during development around PND 7 in rats 
(19). Olney and co-workers have recently reported a sim- 
ilar developmental susceptibility to NMDA toxicity and 
also demonstrated a similar developmental profile for 
hypobaric-ischemic brain injury (1524). In general, the 
effectiveness of drugs in reducing damage induced by 
NMDA parallels their profile of neuroprotective activity 
in perinatal hypoxia-ischemia models (1, 20-22, 30). 
Thus the activity of compounds in this NMDA model 
may predict their effectiveness against hypoxic-isch- 
emit neuronal injury. 
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